Dr. Smith Discusses Novel CAR T-Cell Therapies for Myeloma

Eric Smith, MD, PhD
Published: Thursday, Sep 27, 2018



Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering (MSK) Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Smith says that he spends most of his time in the laboratory, where he makes novel CAR T-cell designs that are aimed at increasing persistence. In myeloma, the CAR T-cell therapy with the most data is bb2121, which has been studied in the relapsed population in US-based clinical trials.

Another novel therapy is JCARH125, which is progressing in clinical trials now, although the results have yet to be reported. JCARH125 is a human-derived CAR T-cell therapy, which may limit the patient's immune response against the CAR T cell, Smith explains.

Other things that are being looked at for the next generation of CAR T-cell therapies include targeting more than 1 target with the same CAR vector. At MSK, Smith and his colleagues have created “armored CAR T cells,” which are modified to not only encode for the CAR, but also for a second gene that encodes a protein. This gives the T cells a further advantage to eradicate the myeloma in the immunosuppressive microenvironment, Smith says.
SELECTED
LANGUAGE


Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering (MSK) Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Smith says that he spends most of his time in the laboratory, where he makes novel CAR T-cell designs that are aimed at increasing persistence. In myeloma, the CAR T-cell therapy with the most data is bb2121, which has been studied in the relapsed population in US-based clinical trials.

Another novel therapy is JCARH125, which is progressing in clinical trials now, although the results have yet to be reported. JCARH125 is a human-derived CAR T-cell therapy, which may limit the patient's immune response against the CAR T cell, Smith explains.

Other things that are being looked at for the next generation of CAR T-cell therapies include targeting more than 1 target with the same CAR vector. At MSK, Smith and his colleagues have created “armored CAR T cells,” which are modified to not only encode for the CAR, but also for a second gene that encodes a protein. This gives the T cells a further advantage to eradicate the myeloma in the immunosuppressive microenvironment, Smith says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x